Join

Compare · NVO vs VTVT

NVO vs VTVT

Side-by-side comparison of Novo Nordisk A/S (NVO) and vTv Therapeutics Inc. (VTVT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and VTVT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $191.15B, about 1594.2x VTVT ($119.9M).
  • Over the past year, NVO is down 44.3% and VTVT is up 93.6% - VTVT leads by 137.9 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 2 for VTVT).
  • NVO has more recent analyst coverage (25 ratings vs 5 for VTVT).
PerformanceNVO-45.90%VTVT+93.58%
2025-06-12+0.00%2026-06-11
MetricNVOVTVT
Company
Novo Nordisk A/S
vTv Therapeutics Inc.
Price
$43.83+2.43%
$31.82+0.03%
Market cap
$191.15B
$119.9M
1M return
-6.68%
+5.96%
1Y return
-44.30%
+93.58%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2015
News (4w)
8
2
Recent ratings
25
5
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

VTVT

vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.